Disturbed MAPK pathway in early bilateral testicular extramedullary relapse of multiple myeloma

被引：2
作者：
Huang, Hai -Fan [1 ]
Xu, Jian [1 ]
Xu, Ao-Shuang [1 ]
Wan, Xiao-Yue [1 ]
Chen, Lei [1 ]
Fan, Feng-Juan [1 ]
Zhang, Bo [1 ]
Tang, Liang [1 ]
Chen, Wan-Xin [1 ]
Sun, Xun [2 ]
Ai, Li-Sha [1 ]
Hou, Jian [3 ]
Sun, Chun-Yan [1 ]
Hu, Yu [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, 1277 Jiefang Dadao, Wuhan 430022, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Nucl Med, Wuhan, Hubei, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Hematol, Shanghai, Peoples R China
来源：
LEUKEMIA RESEARCH | 2020年 / 95卷
基金：
中国国家自然科学基金;
关键词：
DISEASE;
D O I：
10.1016/j.leukres.2020.106403
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 16 条
  • [1] Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon
    Ali, Ridvan
    Ozkalemkas, Fahir
    Ozkan, Atilla
    Ozkocaman, Vildan
    Ozcelik, Tulay
    Ozan, Ulku
    [J]. LEUKEMIA RESEARCH, 2007, 31 (08) : 1153 - 1155
  • [2] Targeting the BRAF V600E Mutation in Multiple Myeloma
    Andrulis, Mindaugas
    Lehners, Nicola
    Capper, David
    Penzel, Roland
    Heining, Christoph
    Huellein, Jennifer
    Zenz, Thorsten
    von Deimling, Andreas
    Schirmacher, Peter
    Ho, Anthony D.
    Goldschmidt, Hartmut
    Neben, Kai
    Raab, Marc S.
    [J]. CANCER DISCOVERY, 2013, 3 (08) : 862 - 869
  • [3] Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma
    Avigdor, A
    Raanani, P
    Levi, I
    Hardan, I
    Ben-Bassat, I
    [J]. LEUKEMIA & LYMPHOMA, 2001, 42 (04) : 683 - +
  • [4] Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
    Blade, Joan
    Fernandez de Larrea, Carlos
    Rosinol, Laura
    Teresa Cibeira, Maria
    Jimenez, Raquel
    Powles, Ray
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) : 3805 - 3812
  • [5] FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
    Fischer, Christian
    Mazzone, Massimiliano
    Jonckx, Bart
    Carmeliet, Peter
    [J]. NATURE REVIEWS CANCER, 2008, 8 (12) : 942 - 956
  • [6] HAYES DW, 1952, AMA ARCH PATHOL, V53, P262
  • [7] Natural history of t(11;14) multiple myeloma
    Lakshman, A.
    Moustafa, M. Alhaj
    Rajkumar, S. V.
    Dispenzieri, A.
    Gertz, M. A.
    Buadi, F. K.
    Lacy, M. Q.
    Dingli, D.
    Fonder, A. L.
    Hayman, S. R.
    Hobbs, M. A.
    Gonsalves, W. I.
    Hwa, Y. L.
    Kapoor, P.
    Leung, N.
    Go, R. S.
    Lin, Y.
    Kourelis, T. V.
    Lust, J. A.
    Russell, S. J.
    Zeldenrust, S. R.
    Kyle, R. A.
    Kumar, S. K.
    [J]. LEUKEMIA, 2018, 32 (01) : 131 - 138
  • [8] Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
    Pour, Ludek
    Sevcikova, Sabina
    Greslikova, Henrieta
    Kupska, Renata
    Majkova, Petra
    Zahradova, Lenka
    Sandecka, Viera
    Adam, Zdenek
    Krejci, Marta
    Kuglik, Petr
    Hajek, Roman
    [J]. HAEMATOLOGICA, 2014, 99 (02) : 360 - 364
  • [9] Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition
    Raab, Marc S.
    Lehners, Nicola
    Xu, Jing
    Ho, Anthony D.
    Schirmacher, Peter
    Goldschmidt, Hartmut
    Andrulis, Mindaugas
    [J]. BLOOD, 2016, 127 (17) : 2155 - 2157
  • [10] Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors
    Rasmussen, T
    Kuehl, M
    Lodahl, M
    Johnsen, HE
    Dahl, IMS
    [J]. BLOOD, 2005, 105 (01) : 317 - 323
12